See more : Inani Securities Limited (INANISEC.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Anavex Life Sciences Corp. (0HFR.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Anavex Life Sciences Corp., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Emlak Konut Gayrimenkul Yatirim Ortakligi A.S. (EKGYO.IS) Income Statement Analysis – Financial Results
- Valmie Resources, Inc. (VMRI) Income Statement Analysis – Financial Results
- Hao Tian International Construction Investment Group Limited (1341.HK) Income Statement Analysis – Financial Results
- Bank of America Corporation (BAC-PQ) Income Statement Analysis – Financial Results
- Ramsdens Holdings PLC (RFX.L) Income Statement Analysis – Financial Results
Anavex Life Sciences Corp. (0HFR.L)
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.25K | 0.00 | 0.00 | 12.00K | 0.00 | 63.11K | 12.81K | 0.00 | 75.00K | 70.00K | 750.00 | 3.00K | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.25K | 0.00 | 0.00 | -12.00K | 0.00 | -63.11K | -12.81K | 0.00 | -75.00K | -70.00K | -750.00 | -3.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 43.72M | 37.92M | 32.98M | 25.23M | 22.26M | 13.34M | 10.67M | 7.25M | 2.27M | 732.40K | 263.85K | 2.65M | 2.60M | 2.73M | 2.14M | 1.48M | 959.70K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 12.04M | 13.07M | 9.02M | 5.86M | 6.85M | 5.99M | 5.01M | 8.33M | 4.84M | 2.24M | 1.87M | 1.55M | 3.44M | 2.91M | 2.59M | 3.79M | 618.22K | 25.48K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 108.14K | 133.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.04M | 13.07M | 9.02M | 5.86M | 6.85M | 5.99M | 5.01M | 8.33M | 4.84M | 2.24M | 1.87M | 1.66M | 3.57M | 2.91M | 2.59M | 3.79M | 618.22K | 25.48K | 91.54K | 0.00 |
| Other Expenses | 0.00 | 3.32M | -54.10K | -149.89K | -298.94K | 1.63M | 2.02M | 151.40K | 0.00 | 199.66K | -976.88K | 1.86K | 10.36K | 910.00 | 410.00 | 220.00 | 0.00 | 115.00 | 0.00 | 0.00 |
| Operating Expenses | 55.76M | 50.99M | 41.95M | 30.94M | 28.81M | 19.18M | 15.54M | 14.88M | 7.11M | 2.97M | 2.13M | 4.32M | 6.18M | 5.64M | 4.73M | 5.27M | 1.58M | 25.59K | 91.54K | 14.47K |
| Cost & Expenses | 55.76M | 50.99M | 41.95M | 30.94M | 28.81M | 19.18M | 15.54M | 14.88M | 7.11M | 2.97M | 2.13M | 4.32M | 6.18M | 5.64M | 4.73M | 5.27M | 1.58M | 25.59K | 91.54K | 14.47K |
| Interest Income | 6.52M | 946.99K | 26.26K | 179.97K | 207.28K | 255.09K | 88.10K | 11.32K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 964.00K | 946.99K | 0.00 | 0.00 | 151.13K | 0.00 | 0.00 | 11.32M | 71.83K | 7.09K | 51.34K | 144.30K | 90.25K | 291.83K | 57.86K | 11.47K | 3.31K | 115.00 | 209.00 | 0.00 |
| Depreciation & Amortization | -2.72M | -3.32M | 37.46M | 26.71M | 26.64M | 17.50M | 1.25K | 1.25K | 995.00 | 768.00 | 576.00 | 1.86K | 1.66K | 910.00 | 410.00 | 220.00 | -1.24K | -59.00 | -125.00 | 0.00 |
| EBITDA | -55.76M | -50.94M | 0.00 | 0.00 | 0.00 | 0.00 | -15.57M | -15.02M | -7.11M | -2.97M | -2.14M | -8.06M | -6.63M | -8.49M | -5.44M | -5.26M | -1.58M | -25.42K | -91.42K | -14.47K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -55.76M | -54.40M | -41.92M | -30.76M | -28.75M | -19.18M | -15.54M | -14.88M | -7.11M | -2.97M | -2.13M | -4.32M | -6.18M | -5.65M | -4.73M | -5.27M | -1.58M | -25.59K | -91.54K | -14.47K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.26M | 3.37M | 4.36M | 4.83M | 3.08M | 2.10M | 2.28M | 881.96K | -5.00M | -8.40M | -1.56M | -3.98M | -1.13M | -3.13M | -765.49K | -81.53K | 1.24K | -56.00 | 125.00 | 0.00 |
| Income Before Tax | -47.50M | -47.62M | -37.64M | -26.26M | -26.21M | -17.38M | -13.40M | -14.71M | -12.11M | -11.37M | -3.70M | -8.16M | -7.22M | -8.50M | -5.44M | -5.28M | -1.58M | -25.53K | -91.42K | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 7.00K | 358.49K | 267.57K | 22.66K | 82.18K | 72.75K | 59.61K | 29.62K | 71.83K | 7.09K | 51.34K | 3.99M | 1.13M | 3.14M | 765.49K | 81.53K | 3.31K | 0.00 | 209.00 | 14.40K |
| Net Income | -47.51M | -47.98M | -37.91M | -26.28M | -26.29M | -17.45M | -13.46M | -14.74M | -12.11M | -11.37M | -3.70M | -8.30M | -7.31M | -8.78M | -5.50M | -5.35M | -1.58M | -25.53K | -91.63K | -14.40K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.60 | -0.62 | -0.54 | -0.45 | -0.54 | -0.39 | -0.33 | -0.42 | -0.65 | -1.16 | -0.46 | -1.18 | -1.16 | -1.64 | -1.09 | -1.09 | -0.33 | -0.01 | -0.02 | -0.01 |
| EPS Diluted | -0.60 | -0.62 | -0.54 | -0.45 | -0.54 | -0.39 | -0.33 | -0.42 | -0.65 | -1.16 | -0.46 | -1.18 | -1.16 | -1.64 | -1.09 | -1.09 | -0.33 | -0.01 | -0.02 | -0.01 |
| Weighted Avg Shares Out | 79.79M | 76.91M | 69.80M | 58.19M | 48.91M | 44.66M | 40.84M | 35.15M | 18.58M | 9.80M | 7.98M | 7.04M | 6.29M | 5.36M | 5.05M | 4.93M | 4.80M | 4.80M | 4.35M | 1.91M |
| Weighted Avg Shares Out (Dil) | 79.79M | 76.91M | 69.80M | 58.19M | 48.91M | 44.66M | 40.84M | 35.15M | 18.58M | 9.80M | 7.98M | 7.04M | 6.29M | 5.36M | 5.05M | 4.93M | 4.80M | 4.80M | 4.35M | 1.91M |
Source: https://incomestatements.info
Category: Stock Reports